



- (51) International Patent Classification:  
*A61K 31/47* (2006.01)
- (21) International Application Number:  
PCT/US2013/049894
- (22) International Filing Date:  
10 July 2013 (10.07.2013)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
61/670,268 11 July 2012 (11.07.2012) US
- (71) Applicant (for BB only): **TEVA PHARMACEUTICAL INDUSTRIES LTD.** [IL/IL]; 5 Basel Street, P.O. Box 3190, 49131 Petach Tikva (IL).
- (71) Applicant (for all designated States except BB, US): **TEVA PHARMACEUTICALS USA, INC.** [US/US]; 1090 Horsham Road, North Wales, PA 19454 (US).
- (72) Inventors; and
- (71) Applicants (for US only): **SARFATII, Gadi** [IL/IL]; Kibbutz Beit Guvrin (IL). **LOVINGER, Ioana** [IL/IL]; Rh. Tel Hai 98/3, 44245 Kfar Saba (IL). **LICHT, Danit** [IL/IL]; Rh. Keren Haysod 1, Givat Shmuel (IL). **SAFADI, Muhammad** [IL/IL]; c/o P.O. Box 50670, St. 5007 Apt. 5A, 16164 Nazareth (IL).
- (74) Agent: **WHITE, John, P.**; Cooper & Dunham LLP, 30 Rockefeller Plaza, New York, NY 10112 (US).

- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: LAQUINIMOD FORMULATIONS WITHOUT ALKALIZING AGENT

(57) Abstract: The subject invention provides a stable pharmaceutical composition comprising a therapeutically effective amount of laquinimod, an amount of a filler, and an amount of a lubricant, wherein the stable pharmaceutical composition is free of an alkalinizing agent or an oxidation reducing agent. The subject invention also provides processes for making the stable pharmaceutical composition and sealed packages comprising the stable pharmaceutical composition. The subject invention additionally provides method for treating a subject afflicted with a form of multiple sclerosis or for alleviating a symptom of multiple sclerosis in a subject afflicted with a form of multiple sclerosis comprising administering to the subject a stable pharmaceutical composition as described herein. The subject invention further provides for use of a stable pharmaceutical composition as described herein for treating a subject afflicted with a form of multiple sclerosis or for alleviating a symptom of multiple sclerosis in a subject afflicted with a form of multiple sclerosis.



**LAQUINIMOD FORMULATIONS WITHOUT ALKALIZING AGENT**

This application claims priority of U.S. Provisional Application No. 61/670,268, filed July 11, 2012, the entire content of which is hereby incorporated by reference herein.

5 Throughout this application various publications, published patent applications, and patents are referenced. The disclosures of these documents in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention pertains.

**10 Background**

Laquinimod is a compound which has been shown to be effective in the acute experimental autoimmune encephalomyelitis (aEAE) model (U.S. Patent No. 6,077,851). Its chemical name is N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide,  
15 and its Chemical Registry number is 248281-84-7. The processes of synthesis of laquinimod and the preparation of its sodium salt are disclosed in U.S. Patent No. 6,077,851. An additional process of synthesis of laquinimod is disclosed in U.S. Patent No. 6,875,869.

Pharmaceutical compositions comprising laquinimod sodium are  
20 disclosed in, e.g., U.S. Patent No. 7,989,473 and PCT International Application Publication No. WO 2005/074899.

Laquinimod sodium has high oral bioavailability and has been suggested as an oral formulation for the treatment of Multiple Sclerosis (MS). (Polman, 2005 and Sandberg-Wollheim, 2005). Studies  
25 have also shown that laquinimod can reduce development of active MRI lesions in relapsing MS. (Polman 2005).

**Summary of the Invention**

The subject invention provides a stable pharmaceutical composition comprising a therapeutically effective amount of laquinimod, an amount of a filler, and an amount of a lubricant, wherein the stable  
5 pharmaceutical composition is free of an alkalizing agent or an oxidation reducing agent.

The subject invention also provides a process for making a stable pharmaceutical composition comprising a therapeutically effective amount of laquinimod, an amount of a filler and an amount of a  
10 lubricant, wherein the pharmaceutical composition is free of an alkalizing agent or an oxidation reducing agent, said process comprising: a) obtaining the laquinimod, the lubricant and the filler;  
b) mixing the laquinimod, the lubricant and the filler from step a) to achieve a dry mix free of an alkalizing agent or an oxidation  
15 reducing agent; and c) compressing the dry mix of step b) to form a tablet.

The subject invention also provides a process for making a stable pharmaceutical composition comprising a therapeutically effective amount of laquinimod, an amount of a filler and an amount of a  
20 lubricant, wherein the pharmaceutical composition is free of an alkalizing agent or an oxidation reducing agent, said process comprising: a) obtaining the laquinimod, the lubricant and the filler;  
b) adding the filler to a mixer; c) dissolving laquinimod in water to form a laquinimod solution; d) adding the laquinimod solution of step  
25 c) to the mixer of step b); e) mixing the laquinimod solution and the mannitol to form a granulate; f) drying the granulate from step e) to form a dried granulate; g) screening the dried granulate of step f);  
h) milling the granulate resulting from step g) to form a milled granulate; i) adding the lubricant to the milled granulate of step h)  
30 to form a mixture; j) blending the mixture of step i) into a mixer to achieve a dry mix free of an alkalizing agent or an oxidation reducing agent; and k) filling the dry mix of step j) into a capsule or compressing the dry mix of step j) to form a tablet.

The subject invention also provides a stable pharmaceutical  
35 composition comprising a therapeutically effective amount of

laquinimod, an amount of a filler and an amount of a lubricant wherein the pharmaceutical composition is free of an alkalizing agent or an oxidation reducing agent, prepared by the processes described herein.

- 5 The subject invention also provides a sealed package comprising the stable pharmaceutical compositions described herein.

The subject invention also provides a sealed package containing a stable pharmaceutical composition comprising a therapeutically effective amount of laquinimod, an amount of a filler and an amount  
10 of a lubricant, wherein the pharmaceutical composition is free of an alkalizing agent or an oxidation reducing agent, and wherein the sealed package has a moisture permeability of not more than 9.2 mg/day per liter.

The subject invention also provides a method for treating a subject  
15 afflicted with a form of multiple sclerosis comprising administering to the subject a stable pharmaceutical composition as described herein so as to thereby treat the subject.


The subject invention also provides a method for alleviating a symptom of multiple sclerosis in a subject afflicted with a form of  
20 multiple sclerosis comprising administering to the subject a stable pharmaceutical composition as described herein so as to thereby alleviate the symptom of multiple sclerosis in the subject.

The subject invention also provides for use of a stable pharmaceutical composition as described herein for treating a  
25 subject afflicted with a form of multiple sclerosis.

The subject invention also provides for use of a stable pharmaceutical composition as described herein for alleviating a symptom of multiple sclerosis in a subject afflicted with a form of multiple sclerosis.

**Detailed Description of the Invention**

Laquinimod is a small molecule having the following chemical structure:



5 laquinimod

It is an oral immunomodulator which has demonstrated therapeutic effect in various experimental inflammatory/autoimmune animal models, such as Experimental Autoimmune Encephalomyelitis (EAE), an animal model for Multiple Sclerosis (MS), Dextran Sodium Sulphate (DSS) induced colitis for Inflammatory Bowel Disease, Non-Obese Diabetic (NOD) mice for Type I Diabetes (IDDM), Experimental Autoimmune Neuritis (EAN) for Guillain-Barre Syndrome, Systemic Lupus Erythematosus (SLE), lupus nephritis, lupus arthritis, Crohn's Disease and Rheumatoid arthritis. The therapeutic activity of laquinimod in these models results from a variety of mechanistic effects, including reduction of leukocyte infiltration into target tissues by modulation of chemokine-mediated T-cell adhesion, modulation of cytokine balance, down regulation of MHC class II resulting in alteration of antigen presentation, and effects on dendritic cells subpopulations.

The inventors have surprisingly found laquinimod formulations which are stable without alkalizing agents. Prior to this invention, it was thought in the art that alkalizing agents were necessary to provide stable laquinimod formulations.

25 Embodiments

The subject invention provides a stable pharmaceutical composition comprising a therapeutically effective amount of laquinimod, an amount of a filler, and an amount of a lubricant, wherein the stable

pharmaceutical composition is free of an alkalizing agent or an oxidation reducing agent.

In an embodiment of the present invention, the stable pharmaceutical composition is in a solid form composition. In another embodiment,  
5 the stable pharmaceutical composition is free of an alkalizing agent and free of an oxidation reducing agent.

In one embodiment, the moisture content of the stable pharmaceutical composition is no more than 4%. In another embodiment, the stable pharmaceutical composition contains less than 1.5% wt H<sub>2</sub>O. In another  
10 embodiment, the stable pharmaceutical composition contains less than 0.5% wt H<sub>2</sub>O. In yet another embodiment, the total amount of non-polar impurities in the composition is less than 0.5 wt% relative to the amount of laquinimod.

In one embodiment, the filler is present in the composition as solid  
15 particles. In another embodiment, the filler is lactose, lactose monohydrate, starch, isomalt, mannitol, sodium starch glycolate, sorbitol, lactose spray dried, lactose anhydrous, or a combination thereof. In yet another embodiment, the filler is mannitol or lactose monohydrate.

20 In one embodiment, the lubricant is present in the composition as solid particles. In another embodiment, the lubricant is magnesium stearate or sodium stearyl fumarate.

In one embodiment, the stable pharmaceutical composition is free of disintegrant. In another embodiment, the stable pharmaceutical composition is free of croscarmellose sodium.

In one embodiment, laquinimod is a pharmaceutically acceptable salt of laquinimod, which pharmaceutically acceptable salt is lithium salt,  
25 sodium salt or calcium salt. In another embodiment, the pharmaceutically acceptable salt of laquinimod is laquinimod sodium.

In one embodiment, laquinimod is present in the composition as solid particles.

In one embodiment, the therapeutically effective amount of laquinimod

is 0.25mg - 1.5mg. In another embodiment, the therapeutically effective amount of laquinimod is 0.5mg. In another embodiment, the therapeutically effective amount of laquinimod is 0.6mg. In another embodiment, the therapeutically effective amount of laquinimod is 1.0mg. In yet another embodiment, the therapeutically effective amount of laquinimod is 1.2mg.

In one embodiment, the lubricant is between 0.5-2.0% of the total weight of the stable pharmaceutical composition. In another embodiment, the filler is between 89.0-99.5% of the total weight of the stable pharmaceutical composition.

In one embodiment, the stable pharmaceutical composition consists essentially of laquinimod sodium, mannitol and magnesium stearate. In another embodiment, the stable pharmaceutical composition comprises, by total weight of the pharmaceutical composition, 0.21-0.35% of the pharmaceutically acceptable salt of laquinimod, 89.0-99.5% mannitol, and 0.5-2.0% magnesium stearate. In another embodiment, the stable pharmaceutical composition comprises, by total weight of the pharmaceutical composition, 0.15-0.35% of the pharmaceutically acceptable salt of laquinimod, 97.65-99.5% mannitol, and 0.5-2.0% magnesium stearate. In another embodiment, the stable pharmaceutical composition comprises, by total weight of the pharmaceutical composition, about 0.21% laquinimod sodium, about 98.80% mannitol and about 0.99% magnesium stearate. In another embodiment, the stable pharmaceutical composition comprises, by total weight of the pharmaceutical composition, 0.21% laquinimod sodium, 98.80% mannitol and 0.99% magnesium stearate. In another embodiment, the stable pharmaceutical composition comprises, by total weight of the pharmaceutical composition, about 0.64mg laquinimod sodium, about 300mg mannitol and about 3.0 mg magnesium stearate. In another embodiment, the stable pharmaceutical composition comprises, by total weight of the pharmaceutical composition, 0.64mg laquinimod sodium, 300mg mannitol and 3.0 mg magnesium stearate. In another embodiment, the stable pharmaceutical composition comprises, by total weight of the pharmaceutical composition, about 0.19% laquinimod sodium, about 98.94% mannitol and about 0.87% magnesium stearate. In another embodiment, the stable pharmaceutical composition comprises, by total

weight of the pharmaceutical composition, 0.19% laquinimod sodium, 98.94% mannitol and 0.87% magnesium stearate.

In one embodiment, 10% or more of the total amount by volume of the laquinimod solid particles have a size of greater than 40 microns.

5 In another embodiment, 50% or more of the total amount by volume of the laquinimod solid particles have a size of greater than 15 microns.

In one embodiment, the stable pharmaceutical composition is in the form of a tablet. In another embodiment, the stable pharmaceutical  
10 composition is in the form of a capsule.

The subject invention also provides a process for making a stable pharmaceutical composition comprising a therapeutically effective amount of laquinimod, an amount of a filler and an amount of a lubricant, wherein the pharmaceutical composition is free of an  
15 alkalizing agent or an oxidation reducing agent, said process comprising: a) obtaining the laquinimod, the lubricant and the filler; b) mixing the laquinimod, the lubricant and the filler from step a) to achieve a dry mix free of an alkalizing agent or an oxidation reducing agent; and c) compressing the dry mix of step b) to form a  
20 tablet.

In an embodiment of the present invention, the process comprises passing the lubricant through a mesh prior to step b). In another embodiment, the process comprises passing the filler through a mesh prior to step b).

25 The subject invention also provides a process for making a stable pharmaceutical composition comprising a therapeutically effective amount of laquinimod, an amount of a filler and an amount of a lubricant, wherein the pharmaceutical composition is free of an alkalizing agent or an oxidation reducing agent, said process  
30 comprising: a) obtaining the laquinimod, the lubricant and the filler; b) adding the filler to a mixer; c) dissolving laquinimod in water to form a laquinimod solution; d) adding the laquinimod solution of step c) to the mixer of step b); e) mixing the laquinimod solution and the mannitol to form a granulate; f) drying the granulate from step e) to

form a dried granulate; g) screening the dried granulate of step f);  
h) milling the granulate resulting from step g) to form a milled  
granulate; i) adding the lubricant to the milled granulate of step h)  
to form a mixture; j) blending the mixture of step i) into a mixer to  
5 achieve a dry mix free of an alkalizing agent or an oxidation  
reducing agent; and k) filling the dry mix of step j) into a capsule  
or compressing the dry mix of step j) to form a tablet.

In an embodiment, the process comprises passing the lubricant through  
a mesh prior to step i). In another embodiment, the process comprises  
10 passing the filler through a mesh prior to step i).

The subject invention also provides a stable pharmaceutical  
composition comprising a therapeutically effective amount of  
laquinimod, an amount of a filler and an amount of a lubricant  
wherein the pharmaceutical composition is free of an alkalizing agent  
15 or an oxidation reducing agent, prepared by the processes described  
herein.

The subject invention also provides a sealed package comprising the  
stable pharmaceutical compositions described herein. In one  
embodiment, the sealed package further comprises a desiccant. In  
20 another embodiment, the desiccant is silica gel.

In one embodiment, the sealed package after storage at 40°C and at a  
relative humidity (RH) of 75% for 2 months contains less than 0.5 wt%  
of a degradant of laquinimod.

The subject invention also provides a sealed package containing a  
25 stable pharmaceutical composition comprising a therapeutically  
effective amount of laquinimod, an amount of a filler and an amount  
of a lubricant, wherein the pharmaceutical composition is free of an  
alkalizing agent or an oxidation reducing agent, and wherein the  
sealed package has a moisture permeability of not more than 9.2  
30 mg/day per liter.

The subject invention also provides a method for treating a subject  
afflicted with a form of multiple sclerosis comprising administering  
to the subject a stable pharmaceutical composition as described

herein so as to thereby treat the subject.

The subject invention also provides a method for alleviating a symptom of multiple sclerosis in a subject afflicted with a form of multiple sclerosis comprising administering to the subject a stable pharmaceutical composition as described herein so as to thereby  
5 alleviate the symptom of multiple sclerosis in the subject.

The subject invention also provides for use of a stable pharmaceutical composition as described herein for treating a subject afflicted with a form of multiple sclerosis.

10 The subject invention also provides for use of a stable pharmaceutical composition as described herein for alleviating a symptom of multiple sclerosis in a subject afflicted with a form of multiple sclerosis.

For the foregoing embodiments, each embodiment disclosed herein is  
15 contemplated as being applicable to each of the other disclosed embodiments.

A dosage unit may comprise a single compound or mixtures of compounds thereof. A dosage unit can be prepared for oral dosage forms, such as tablets, capsules, pills, powders, and granules.

20 Laquinimod can be administered in admixture with suitable pharmaceutical diluents, extenders, excipients, or carriers (collectively referred to herein as a pharmaceutically acceptable carrier) suitably selected with respect to the intended form of administration and as consistent with conventional pharmaceutical  
25 practices. The unit will be in a form suitable for oral administration. Laquinimod can be administered alone but is generally mixed with a pharmaceutically acceptable carrier, and co-administered in the form of a tablet or capsule, liposome, or as an agglomerated powder. Examples of suitable solid carriers include  
30 lactose, sucrose, gelatin and agar.

Capsule or tablets can be formulated and can be made easy to swallow or chew; other solid forms include granules and bulk powders. Tablets may contain suitable binders, lubricants, diluents,

disintegrating agents (disintegrants), coloring agents, flavoring agents, flow-inducing agents, and melting agents. For instance, for oral administration in the dosage unit form of a tablet or capsule, the active drug component can be combined with an oral, non-toxic, pharmaceutically acceptable, inert carrier such as lactose, gelatin, agar, starch, sucrose, glucose, methyl cellulose, dicalcium phosphate, calcium sulfate, mannitol, sorbitol, microcrystalline cellulose and the like. Suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn starch, natural and synthetic gums such as acacia, tragacanth, or sodium alginate, povidone, carboxymethylcellulose, polyethylene glycol, waxes, and the like. Lubricants used in these dosage forms include sodium oleate, sodium stearate, sodium benzoate, sodium acetate, sodium chloride, stearic acid, sodium stearyl fumarate, talc and the like. Disintegrants include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum, croscarmellose sodium, sodium starch glycolate and the like.

Specific examples of the techniques, pharmaceutically acceptable carriers and excipients that may be used to formulate oral dosage forms of the present invention are described, e.g., in U.S. Patent Application Publication No. 2005/0192315, PCT International Application Publication Nos. WO 2005/074899, WO 2007/047863, and WO/2007/146248, each of which is hereby incorporated by reference into this application.

General techniques and compositions for making dosage forms useful in the present invention are described in the following references: 7 Modern Pharmaceutics, Chapters 9 and 10 (Banker & Rhodes, Editors, 1979); Pharmaceutical Dosage Forms: Tablets (Lieberman et al., 1981); Ansel, Introduction to Pharmaceutical Dosage Forms 2nd Edition (1976); Remington's Pharmaceutical Sciences, 17th ed. (Mack Publishing Company, Easton, Pa., 1985); Advances in Pharmaceutical Sciences (David Ganderton, Trevor Jones, Eds., 1992); Advances in Pharmaceutical Sciences Vol 7. (David Ganderton, Trevor Jones, James McGinity, Eds., 1995); Aqueous Polymeric Coatings for Pharmaceutical Dosage Forms (Drugs and the Pharmaceutical Sciences, Series 36 (James McGinity, Ed., 1989); Pharmaceutical Particulate Carriers:

Therapeutic Applications: Drugs and the Pharmaceutical Sciences, Vol 61 (Alain Rolland, Ed., 1993); Drug Delivery to the Gastrointestinal Tract (Ellis Horwood Books in the Biological Sciences. Series in Pharmaceutical Technology; J. G. Hardy, S. S. Davis, Clive G. Wilson, Eds.); Modern Pharmaceutics Drugs and the Pharmaceutical Sciences, Vol. 40 (Gilbert S. Banker, Christopher T. Rhodes, Eds.). These references in their entireties are hereby incorporated by reference into this application.

### Terms

10 As used herein, and unless stated otherwise, each of the following terms shall have the definition set forth below.

As used herein, "laquinimod" means laquinimod acid or a pharmaceutically acceptable salt thereof.

A "salt" is salt of the instant compounds which have been modified by making acid or base salts of the compounds. The term "pharmaceutically acceptable salt" in this respect, refers to the relatively non-toxic, inorganic and organic acid or base addition salts of compounds of the present invention. A pharmaceutically acceptable salt of laquinimod as used in this application includes 15 lithium, sodium, potassium, magnesium, calcium, manganese, copper, zinc, aluminum and iron. Salt formulations of laquinimod and the process for preparing the same are described, e.g., in U.S. Patent No. 7,589,208 and PCT International Application Publication No. WO 2005/074899, which are hereby incorporated by reference into this 20 application.

As used herein, "alkalizing agent" is used interchangeably with the term "alkaline-reacting component" or "alkaline agent" and refers to any pharmaceutically acceptable excipient which neutralizes protons in, and raises the pH of, the pharmaceutical composition in which it 30 is used.

As used herein, "oxidation reducing agent" refers to a group of chemicals which includes an "antioxidant", a "reduction agent" and a "chelating agent".

As used herein, "antioxidant" refers to a compound selected from the group consisting of tocopherol, methionine, glutathione, tocotrienol, dimethyl glycine, betaine, butylated hydroxyanisole, butylated hydroxytoluene, turmerin, vitamin E, ascorbyl palmitate, tocopherol, 5 deteroxime mesylate, methyl paraben, ethyl paraben, butylated hydroxyanisole, butylated hydroxytoluene, propyl gallate, sodium or potassium metabisulfite, sodium or potassium sulfite, alpha tocopherol or derivatives thereof, sodium ascorbate, disodium edentate, BHA (butylated hydroxyanisole), a pharmaceutically acceptable salt or 10 ester of the mentioned compounds, and mixtures thereof.

The term "antioxidant" as used herein also refers to flavonoids such as those selected from the group of quercetin, morin, naringenin and hesperetin, taxifolin, afzelin, quercitrin, myricitrin, genistein, apigenin and biochanin A, flavone, flavopiridol, isoflavonoids such 15 as the soy isoflavonoid, genistein, catechins such as the tea catechin epigallocatechin gallate, flavonol, epicatechin, hesperetin, chrysin, diosmin, hesperidin, luteolin, and rutin.

As used herein, "reduction agent" refers to a compound selected from the group consisting of thiol-containing compound, thioglycerol, 20 mercaptoethanol, thioglycol, thiodiglycol, cysteine, thioglucose, dithiothreitol (DTT), dithio-bis-maleimidoethane (DTME), 2,6-di-tert-butyl-4-methylphenol (BHT), sodium dithionite, sodium bisulphite, formamidine sodium metabisulphite, and ammonium bisulphite.

As used herein, "chelating agent" refers to a compound selected from 25 the group consisting of penicillamine, trientine, N,N'-diethyldithiocarbamate (DDC), 2,3,2'-tetraamine (2,3,2'-tet), neocuproine, N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine (TPEN), 1,10-phenanthroline (PHE), tetraethylenepentamine, triethylenetetraamine and tris(2-carboxyethyl) phosphine (TCEP), 30 ferrioxamine, CP94, EDTA, deferoxamine B (DFO) as the methanesulfonate salt (also known as desferrioxamine B mesylate (DFOM)), desferal from Novartis (previously Ciba-Giegy), and apoferritin.

As used herein, a composition that is "free" of a chemical entity 35 means that the composition contains, if at all, an amount of the

chemical entity which cannot be avoided although the chemical entity is not part of the formulation and was not affirmatively added during any part of the manufacturing process. For example, a composition which is "free" of an alkalizing agent means that the alkalizing agent, if present at all, is a minority component of the composition by weight. Preferably, when a composition is "free" of a component, the composition comprises less than 0.1 wt%, 0.05 wt%, 0.02 wt%, or 0.01 wt% of the component.

As used herein, "about" in the context of a numerical value or range means  $\pm 10\%$  of the numerical value or range recited or claimed.

An "amount" or "dose" of laquinimod as measured in milligrams refers to the milligrams of laquinimod acid present in a preparation, regardless of the form of the preparation.

The term "stable pharmaceutical composition" as used herein in connection with the composition according to the invention denotes a composition, which preserves the physical stability/integrity and/or chemical stability/integrity of the active pharmaceutical ingredient during storage. Furthermore, "stable pharmaceutical composition" is characterized by its level of degradation products not exceeding 5% at 40°C/75%RH after 6 months or 3% at 55°C/75% RH after two weeks, compared to their level in time zero.

As used herein, "treating" encompasses, e.g., inducing inhibition, regression, or stasis of a disease, disorder or condition, or ameliorating or alleviating a symptom of a disease, disorder or condition. "Ameliorating" or "alleviating" a condition or state as used herein shall mean to relieve or lessen the symptoms of that condition or state. "Inhibition" of disease progression or disease complication in a subject as used herein means preventing or reducing the disease progression and/or disease complication in the subject.

As used herein, "effective" as in an amount effective to achieve an end, i.e., "therapeutically effective amount", means the quantity of a component that is sufficient to yield an indicated therapeutic response without undue adverse side effects (such as toxicity, irritation, or allergic response) commensurate with a reasonable

benefit/risk ratio when used in the manner of this disclosure. For example, an amount effective to treat a subject afflicted with a form of multiple sclerosis. The specific effective amount will vary with such factors as the particular condition being treated, the physical condition of the patient, the type of mammal being treated, the duration of the treatment, the nature of concurrent therapy (if any), and the specific formulations employed and the structure of the compounds or its derivatives.

"Administering to the subject" means the giving of, dispensing of, or application of medicines, drugs, or remedies to a subject to relieve, cure, or reduce the symptoms associated with a condition, e.g., a pathological condition.

As used herein, "pharmaceutically acceptable carrier" refers to a carrier or excipient that is suitable for use with humans and/or animals without undue adverse side effects (such as toxicity, irritation, and allergic response) commensurate with a reasonable benefit/risk ratio. It can be a pharmaceutically acceptable solvent, suspending agent or vehicle, for delivering the instant compounds to the subject. "Pharmaceutically acceptable carrier" includes "fillers", which fill out the size of a tablet or capsule, making it practical to produce and convenient for the consumer to use. By increasing the bulk volume, the fillers make it possible for the final product to have the proper volume for patient handling. "Pharmaceutically acceptable carrier" also includes "lubricants", which prevent ingredients from clumping together and from sticking to the tablet punches or capsule filling machine. Lubricants also ensure that tablet formation and ejection can occur with low friction between the solid and die wall.

It is understood that where a parameter range is provided, all integers within that range, and tenths and hundredth thereof, are also provided by the invention. For example, "0.15-0.35%" includes 0.15%, 0.16%, 0.17% etc. up to 0.35%.

This invention will be better understood by reference to the Experimental Details which follow, but those skilled in the art will readily appreciate that the specific experiments detailed are only

illustrative of the invention as described more fully in the claims which follow thereafter.

### Experimental Details

5 Example 1: Compatibility of laquinimod sodium with fillers, with or without addition of water

In HDPE securitainers (canister) several binary blends were prepared containing laquinimod sodium and a filler (mannitol or lactose), with or without water, as presented in Table 1.

Table 1: Dry and wet compositions of laquinimod sodium with fillers

Batch No.	Active Material	Excipient	Water
1	Laquinimod sodium 1	Mannitol 300mg (466.66)	-
2	Laquinimod sodium 1	Mannitol 300mg (466.66)	+
3	Laquinimod sodium 1	Lactose monohydrate 160mg (248.88)	-
4	Laquinimod sodium 1	Lactose monohydrate 160mg (248.99)	+

10

Preparing Batches 1 and 3 (dry) and Batches 2 and 4 (wet)

The dry blend was prepared by placing 4.5 mg laquinimod sodium and 2.1g mannitol or 1.12g lactose monohydrate into a plastic securitainer (HDPE canister). The securitainers were closed with a polypropylene cap and were placed into a V type blender. Then they were mixed for 10 minutes to form Batch 1 and Batch 3.

The wet blend was prepared by placing 4.5 mg laquinimod sodium and 2.1g mannitol or 1.12g lactose monohydrate into a plastic securitainer (HDPE canister). The securitainers were closed with polypropylene cap and were placed into a V-blender. Then they were mixed for 10 minutes to form Batch 2 and Batch 4. The polypropylene cap was then opened, and 10 drops of water were added to each securitainer, and the content was mixed with a spatula to ensure wetting of the powder. The securitainers were closed again with the polypropylene caps.

All the blends were placed into stability chamber at 55°C for two weeks.

After two weeks the blends were tested for Assay, Polar and Non Polar IDD. The results are presented in Tables 2 and 3.

Table 2: Results of the dry vs. wet compositions

Batch No.	5-HLAQ	MCQ & MCQCA	MCQME	MCQEE	RRT ~0.19	RRT ~0.20	RRT ~0.22	RRT ~1.20	Total
1	-	-	-	-	-	0.08	0.04	-	0.12
2	<0.05	0.40	<0.02	<0.02	0.11	0.08	0.05	0.24	0.88

5 Table 3: Results of the dry vs. wet compositions

Batch No.	5-HLAQ	RRT ~0.14	RRT ~0.17	RRT ~0.18	RRT ~0.21	RRT ~0.23~0.81	RRT ~1.17	RRT ~1.50	Total
3	-	0.01	0.03	0.01	-	-	0.05	0.03	0.13
4	0.05	-	0.09	-	0.09	0.14	-	0.03	0.40

No significant Non Polar Impurities were obtained in all compositions.

10 According to the results presented in Table 2 and Table 3, superior stability results were obtained in the dry blends (Batches 1 and 3), compared to the wet blends in both formulations.

In the laquinimod sodium - mannitol wet blend (Batch 2), a total of 0.88% Polar IDD was obtained while the dry blend (Batch 1), obtained a total of 0.12% Polar IDD.

15 In laquinimod sodium-lactose wet blend (Batch 4), a total of 0.40% Polar IDD was obtained while the dry blend (Batch 3) obtained a total of 0.13% Polar IDD.

20 In order to evaluate the differences between dry and wet manufacturing processes, a comparison was made between capsules prepared by a dry mix process vs. capsules prepared by wet granulation, with Pruv® (sodium stearyl fumarate) as a lubricant. The capsules were packed in 50cc Duma® bottles with polypropylene cap (2g silica gel inserted in cap). The compositions of the dry formulation (Batch 5) and the wet formulation (Batch 6), without  
25 alkalizing agent, are presented in Table 4.

Table 4: Dry mix and wet granulation formulations

Composition (mg)	Batch No.	
	5	6
Laquinimod sodium	0.64	0.64
Mannitol	300.00	340.00
Pruv®	3.0	3.4
Total	303.64	344.04

Manufacturing Batches 5 and 6

Batch 5 (Dry)

- 5 Mannitol was screened using a 30 mesh sieve and inserted with laquinimod sodium into a V type blender. The mixture was then blended for 15 minutes. The lubricant (Pruv®) was screened using a 50 mesh sieve, added to the V type blender and blended for an additional 5 minutes.
- 10 304mg of the final blend were then filled into size 1 white opaque gelatin capsules. The capsules were packed into 50cc Duma® bottles with polypropylene cap (2g silica gel inserted in cap).

The capsules were placed in a stability chamber at 40°C/75%RH for 3 months and tested for Assay, Dissolution, Polar and Non Polar IDD.

15 Batch 6 (Wet)

- For the purpose of manufacturing Batch 6, mannitol was placed into a high shear mixer. Laquinimod sodium was dissolved in purified water and was added to the mannitol. The mannitol and the granulation solution were mixed in the high shear mixer to obtain the desired granulate.
- 20

The granulate obtained was dried in a Fluid Bed Dryer until a loss on drying (LOD) of not more than 0.5% was obtained. The dried granulate was milled using a 0.8mm screen. The milled granulate was transferred to the V type blender.

- 25 Lubricant (PRUV®) was screened using a 50 mesh sieve, added to the V type blender and blended for an additional 5 minutes.

344mg of the final blend were then filled into size 1 white opaque gelatin capsules. The capsules were packed into 50cc Duma® bottles with polypropylene cap (2g silica gel inserted in cap).

The capsules (Batches 5 and 6) were placed in a stability chamber at accelerated conditions for 3 months. The results for Polar IDD are shown in Table 5.

Table 5:

Batch	Interval	MCQ +MCQCA	Any other impurities at RRT				Total Polar IDD
			~0.15	~0.18	~0.20	~1.29	
			~0.17	~0.19	~0.28	~1.42	
5 (Dry mix, Pruv®, Duma®)	T <sub>0</sub>	<0.02					<0.05
	3 M	0.06		0.13	<0.02		0.19
6 (Wet granulation, Pruv®, Duma®)	T <sub>0</sub>	<0.05		<0.05	<0.05	-	<0.05
	2 M	0.26		0.16	<0.05	-	0.42
	3 M	0.48		0.31	0.08	0.05	0.92

No significant Non Polar IDD was obtained in both granulates. Similar to compatibility results before, after 3 months at accelerated conditions, total Polar IDD obtained in dry blend (Batch 5) is 0.19%, which is better than total Polar IDD of 0.92% obtained in wet granulation (Batch 6).

Example 2: Packaging influence on batches manufactured using a wet granulation process

A comparison was made between stability results obtained at accelerated conditions of capsules manufactured using wet granulation process, which were packed in HDPE bottles with and without a desiccant (silica gel) (Batch 6 versus Batch 7). The proportional formulations tested are presented in Table 6.

Table 6:

Composition (mg)	Batch No.	
	6 (capsules)	7 (capsules)
Laquinimod	0.64	0.32
Mannitol	340.00	170.0
Pruv®	3.4	1.6
Total	344.04	171.9

The manufacturing of Batch 6 was described in Example 1.

Manufacturing Batch 7

- 5 Mannitol was placed into a high shear mixer. Laquinimod sodium was dissolved in purified water and added to the mannitol. The mannitol and the granulation solution were mixed in the high shear mixer to obtain the desired granulate.

10 The granulate obtained was dried in a Fluid Bed Dryer until a loss on drying (LOD) of not more than 0.5% was obtained. The dried granulate was milled using a 0.8mm screen. The milled granulate was transferred to the V type blender.

Lubricant (PRUV®) was screened using a 50mesh sieve, added to the V type blender and blended for an additional 5 minutes.

- 15 The final blend was filled into orange opaque hard gelatin capsules, size 3 (weight: 171.9mg/capsule) and the capsules were packed into 30cc HDPE bottles with induction liner and polypropylene cap without silica gel.

20 The capsules were placed in stability chamber at accelerated conditions for 2 months. Results for Polar IDD are presented in Table 7.

Table 7:

Batch No.	Interval	MCQ + MCQCA	Any other impurities at RRT					Total
			~0.15 ~0.17	~0.18 ~0.19	~0.20 ~0.29	~1.29 ~1.42	Each	
Specification		NMT:0.5%	NMT:0.5%					NMT 2.0%
7 (Induction without Silica Gel)	T <sub>0</sub>	<0.02	-	-	-	-	-	0.07
	1 M	0.79	-	0.27	0.07	0.13	-	1.26
	2 M	1.74	0.05		0.43			2.22
6 (Duma®)	T <sub>0</sub>	<0.05	-	<0.05	<0.05	-	-	<0.05
	1 M	0.15	-	0.08	<0.05	<0.05	-	0.23
	2 M	0.26	-	0.16	<0.05	-	-	0.42
	3 M	0.48	-	0.31	0.08	0.05	-	0.92

No significant Non Polar IDD was obtained in both packaging configurations.

- 5 After 2 months at accelerated conditions, high impurity levels were obtained in HDPE bottles without desiccant (Batch 7) with total Polar IDDs 2.22% vs. 0.42% in Duma® bottle with polypropylene cap and 2g silica gel inserted in cap (Batch 6).

Example 3: Lubricant influence in dry blend

- 10 Based on the results obtained in compatibility between laquinimod and mannitol in dry blend (Batch 1), two different lubricants were added to this combination without addition of alkalizing agent. A dry blend (Batch 5) was prepared from laquinimod, mannitol and Pruv® (Sodium Stearyl Fumarate) and other dry blend (Batch 8) was prepared  
15 from laquinimod, mannitol and magnesium stearate as presented in Table 8.

Table 8: Dry blend formulations with different Lubricant

Composition	Batch No.	
	<b>5</b>	<b>8</b>
Laquinimod	0.64	0.64
Mannitol USP/BP	300.00	300.00
Mg. Stearate	-	3.0
Pruv®	3.0	-
Total	303.64	303.64

Manufacturing Batch 8

Mannitol was passed through sieve 30mesh and then blend with laquinimod into y-cone for 15 minutes. The lubricant (Pruv®/magnesium stearate) was passed through sieve 50mesh and was added to the blend of laquinimod with mannitol, then continued blending for 5 minutes.

The blend was filled into size 1, white opaque gelatin capsules (weight: 303.64mg/capsule). The capsules were packed into 50cc Duma® bottles with polypropylene cap (2g silica gel inserted in cap).

The capsules were placed in stability chamber at 40°C/75%RH for 6 months and tested for Assay, Dissolution, Polar and Non Polar IDD. The results are shown in Table 9 (Polar IDD (%) at 40°C/75%RH).

Table 9: The influence of different lubricant

Batch No.	Interval	MCQ + MCQCA	Any other impurities at RRT				Total Polar IDD	DIS 30min	Water
			~0.15 ~0.17	~0.18 ~0.19	~0.20 ~0.28	~1.29 ~1.42			
5 (Pruv® Duma®)	T <sub>0</sub>	<0.02					<0.05	93	0.08
	3 M	0.06		0.13	<0.02		0.19	95	0.04
	6 M	0.25		0.51	0.15		0.91	96	0.05
8 (Magnesium stearate, Duma®)	T <sub>0</sub>	<0.03					<0.05	97	0.08
	3 M	<0.03		<0.02	<0.02		<0.05	99	0.05
	6 M	<0.03		0.05			<0.05	99	0.06

15

No significant non polar impurities were obtained in both formulations.

After 6 months at accelerated conditions, low impurities (Total Polar IDD: <0.05%) were obtained in capsules with magnesium stearate as lubricant (batch 8). In capsules with Pruv® as lubricant (batch 5), the impurities were higher than in capsules with magnesium stearate (total Polar IDD: 0.91%) but the results were still within specifications (NMT 2%). Sum of MCQ+MCQCA obtained was 0.25%, which is still within specifications (NMT 0.5%).

20

Example 4: Tablet formulations using different fillers

Two dry blends were prepared and tablets were pressed. The first blend (Batch 9) is a combination of laquinimod and Mannitol Partek M200 as filler and the second blend (Batch 10) is a combination of laquinimod and lactose spray dried as filler. In both blends magnesium stearate was used as lubricant. The two blends without alkalizing agent are presented in Table 10.

Table 10: Tablets formulation with different fillers

Composition	Batch No.	
	9 (tablets.)	10 (tablets)
Laquinimod	0.64	0.64
Mannitol (Partek M200 in tablets)	300.36	-
Lactose SD	-	300.36
Magnesium Stearate	3.00	1.50
Total	304.00	302.50

10 Manufacturing Batches 9 and 10

Mannitol Partek or lactose spray dried and laquinimod sodium were mixed into Y-cone for 10 minutes. Magnesium stearate was passed through mesh 50 and was added to the Y-cone and continued mixing for 5 minutes. Tablets were pressed by Sviac press machine. The tablets were packed in 50cc HDPE Duma® bottles with polypropylene cap (2g silica gel inserted in cap) and placed in stability chamber at 40°C/75%RH for 6 months. The results are presented in Table 11 (Polar IDD (%) at 40°C/75%RH).

Table 11: The influence of different fillers in tablets formulation

Batch No.	Interval	MCQ + MCQCA	Any other impurities at RRT					Total
			~0.15 ~0.17	~0.18 ~0.19	~0.20 ~0.29	~1.29 ~1.42	Each	
<b>Specification</b>		NMT:0.5%	NMT:0.5%					NMT:2.0%
<b>9 (Mannitol, Duma®)</b>	T <sub>0</sub>	<0.03	-	-	-	-	<0.02	<0.05
	3 M	<0.03	-	-	-	-	<0.02	<0.05
	6 M	<0.03	-	-	-	-	<0.02	<0.05
<b>10 (Lactose, Duma®)</b>	T <sub>0</sub>	<0.03	-	-	-	-	-	<0.1
	3 M	0.07	-	-	-	-	-	0.07
	6 M	0.18		0.05	0.07			0.3

No significant Non Polar IDD was obtained.

The results obtained after 6 months were satisfactory in both  
5 formulations: Total Polar IDD in tablets with mannitol was <0.05%  
and 0.3% in tablets with lactose.

Example 5: Comparison between capsules and tablets without  
alkalizing agent

Batches 8 and 9 were manufactured according to previously described  
10 procedure in order to compare capsules and tablets without  
alkalizing agent. The two blends without alkalizing agent are  
presented in Table 12.

Table 12: Composition of capsules and tablets

Composition	Batch No.	
	8 (capsules)	9 (tablets)
Laquinimod	0.64	0.64
Mannitol (Partek M200 in tablets)	300.00	300.36
Magnesium Stearate	3.0	3.00
<b>Total</b>	<b>303.64</b>	<b>304.00</b>

15 A comparison between capsules and tablets, formulated from dry blend  
laquinimod sodium, mannitol and magnesium stearate as lubricant

(without an alkalizing agent) provided, in both formulations, good results (table 13; Polar IDD (%) at 40°C/75%RH).

Table 13: Capsules vs. tablets

Batch No.	Interval	MCQ + MCQCA	Any other impurities at RRT				Each	Total
			~0.15 ~0.17	~0.18 ~0.19	~0.20 ~0.28	~1.29 ~1.42		
Specification		NMT:0.5%	NMT:0.5%					NMT 2.0%
8 (Capsules, Dry blend)	T <sub>0</sub>	<0.03						<0.05
	3 M	<0.03		<0.02	<0.02			<0.05
	6 M	<0.03		0.05				<0.05
9 (Tablets, Dry blend)	T <sub>0</sub>	<0.03					<0.02	<0.05
	3 M	<0.03					<0.02	<0.05
	6 M	<0.03					<0.02	<0.05

- 5 Batches 8 and 9, which were packaged in DUMA® bottles (containing 2g desiccant) and did not contain an alkalizing agent, had shown that at accelerated conditions, for up to 6 months, no impurities were formed. Two additional batches (Batches 16 and 17) were manufactured to assess the effect of a disintegrant (croscarmellose sodium) on
- 10 the dissolution rate of the tablets. Stability of the batches at 55°C/ 75% RH and at accelerated conditions was tested. The batches were manufactured using a dry granulation process with milling. Both batches were then packaged in LOG 60ml bottles, with or without 1g silica gel (Batches 16A; 16B; 17A; 17B) are described in Table 14.
- 15 Table 14: Formulation without alkalizing agent, with or without disintegrant and with or without desiccant

Composition	Batch Number			
	16A	16B	17A	17B
Mannitol	+	+	+	+
Laquinimod Sodium	+	+	+	+
Magnesium Stearate	+	+	+	+
Croscarmellose Sodium (Ac-Di-Sol)	-	-	+	+
Silica gel 1g	+	-	+	-

Stability results of these batches at 55°C/75% RH and 40°C/75% RH, for up to 1 month did not show a major increase in impurities. The presence of 1g desiccant was shown to have a good impact on stability by decreasing the level of impurities (Table 15; Polar  
 5  
 10  
 15  
 20  
 25  
 30  
 35  
 40  
 45  
 50  
 55  
 60  
 65  
 70  
 75  
 80  
 85  
 90  
 95  
 100  
 105  
 110  
 115  
 120  
 125  
 130  
 135  
 140  
 145  
 150  
 155  
 160  
 165  
 170  
 175  
 180  
 185  
 190  
 195  
 200  
 205  
 210  
 215  
 220  
 225  
 230  
 235  
 240  
 245  
 250  
 255  
 260  
 265  
 270  
 275  
 280  
 285  
 290  
 295  
 300  
 305  
 310  
 315  
 320  
 325  
 330  
 335  
 340  
 345  
 350  
 355  
 360  
 365  
 370  
 375  
 380  
 385  
 390  
 395  
 400  
 405  
 410  
 415  
 420  
 425  
 430  
 435  
 440  
 445  
 450  
 455  
 460  
 465  
 470  
 475  
 480  
 485  
 490  
 495  
 500  
 505  
 510  
 515  
 520  
 525  
 530  
 535  
 540  
 545  
 550  
 555  
 560  
 565  
 570  
 575  
 580  
 585  
 590  
 595  
 600  
 605  
 610  
 615  
 620  
 625  
 630  
 635  
 640  
 645  
 650  
 655  
 660  
 665  
 670  
 675  
 680  
 685  
 690  
 695  
 700  
 705  
 710  
 715  
 720  
 725  
 730  
 735  
 740  
 745  
 750  
 755  
 760  
 765  
 770  
 775  
 780  
 785  
 790  
 795  
 800  
 805  
 810  
 815  
 820  
 825  
 830  
 835  
 840  
 845  
 850  
 855  
 860  
 865  
 870  
 875  
 880  
 885  
 890  
 895  
 900  
 905  
 910  
 915  
 920  
 925  
 930  
 935  
 940  
 945  
 950  
 955  
 960  
 965  
 970  
 975  
 980  
 985  
 990  
 995  
 1000  
 1005  
 1010  
 1015  
 1020  
 1025  
 1030  
 1035  
 1040  
 1045  
 1050  
 1055  
 1060  
 1065  
 1070  
 1075  
 1080  
 1085  
 1090  
 1095  
 1100  
 1105  
 1110  
 1115  
 1120  
 1125  
 1130  
 1135  
 1140  
 1145  
 1150  
 1155  
 1160  
 1165  
 1170  
 1175  
 1180  
 1185  
 1190  
 1195  
 1200  
 1205  
 1210  
 1215  
 1220  
 1225  
 1230  
 1235  
 1240  
 1245  
 1250  
 1255  
 1260  
 1265  
 1270  
 1275  
 1280  
 1285  
 1290  
 1295  
 1300  
 1305  
 1310  
 1315  
 1320  
 1325  
 1330  
 1335  
 1340  
 1345  
 1350  
 1355  
 1360  
 1365  
 1370  
 1375  
 1380  
 1385  
 1390  
 1395  
 1400  
 1405  
 1410  
 1415  
 1420  
 1425  
 1430  
 1435  
 1440  
 1445  
 1450  
 1455  
 1460  
 1465  
 1470  
 1475  
 1480  
 1485  
 1490  
 1495  
 1500  
 1505  
 1510  
 1515  
 1520  
 1525  
 1530  
 1535  
 1540  
 1545  
 1550  
 1555  
 1560  
 1565  
 1570  
 1575  
 1580  
 1585  
 1590  
 1595  
 1600  
 1605  
 1610  
 1615  
 1620  
 1625  
 1630  
 1635  
 1640  
 1645  
 1650  
 1655  
 1660  
 1665  
 1670  
 1675  
 1680  
 1685  
 1690  
 1695  
 1700  
 1705  
 1710  
 1715  
 1720  
 1725  
 1730  
 1735  
 1740  
 1745  
 1750  
 1755  
 1760  
 1765  
 1770  
 1775  
 1780  
 1785  
 1790  
 1795  
 1800  
 1805  
 1810  
 1815  
 1820  
 1825  
 1830  
 1835  
 1840  
 1845  
 1850  
 1855  
 1860  
 1865  
 1870  
 1875  
 1880  
 1885  
 1890  
 1895  
 1900  
 1905  
 1910  
 1915  
 1920  
 1925  
 1930  
 1935  
 1940  
 1945  
 1950  
 1955  
 1960  
 1965  
 1970  
 1975  
 1980  
 1985  
 1990  
 1995  
 2000  
 2005  
 2010  
 2015  
 2020  
 2025  
 2030  
 2035  
 2040  
 2045  
 2050  
 2055  
 2060  
 2065  
 2070  
 2075  
 2080  
 2085  
 2090  
 2095  
 2100  
 2105  
 2110  
 2115  
 2120  
 2125  
 2130  
 2135  
 2140  
 2145  
 2150  
 2155  
 2160  
 2165  
 2170  
 2175  
 2180  
 2185  
 2190  
 2195  
 2200  
 2205  
 2210  
 2215  
 2220  
 2225  
 2230  
 2235  
 2240  
 2245  
 2250  
 2255  
 2260  
 2265  
 2270  
 2275  
 2280  
 2285  
 2290  
 2295  
 2300  
 2305  
 2310  
 2315  
 2320  
 2325  
 2330  
 2335  
 2340  
 2345  
 2350  
 2355  
 2360  
 2365  
 2370  
 2375  
 2380  
 2385  
 2390  
 2395  
 2400  
 2405  
 2410  
 2415  
 2420  
 2425  
 2430  
 2435  
 2440  
 2445  
 2450  
 2455  
 2460  
 2465  
 2470  
 2475  
 2480  
 2485  
 2490  
 2495  
 2500  
 2505  
 2510  
 2515  
 2520  
 2525  
 2530  
 2535  
 2540  
 2545  
 2550  
 2555  
 2560  
 2565  
 2570  
 2575  
 2580  
 2585  
 2590  
 2595  
 2600  
 2605  
 2610  
 2615  
 2620  
 2625  
 2630  
 2635  
 2640  
 2645  
 2650  
 2655  
 2660  
 2665  
 2670  
 2675  
 2680  
 2685  
 2690  
 2695  
 2700  
 2705  
 2710  
 2715  
 2720  
 2725  
 2730  
 2735  
 2740  
 2745  
 2750  
 2755  
 2760  
 2765  
 2770  
 2775  
 2780  
 2785  
 2790  
 2795  
 2800  
 2805  
 2810  
 2815  
 2820  
 2825  
 2830  
 2835  
 2840  
 2845  
 2850  
 2855  
 2860  
 2865  
 2870  
 2875  
 2880  
 2885  
 2890  
 2895  
 2900  
 2905  
 2910  
 2915  
 2920  
 2925  
 2930  
 2935  
 2940  
 2945  
 2950  
 2955  
 2960  
 2965  
 2970  
 2975  
 2980  
 2985  
 2990  
 2995  
 3000  
 3005  
 3010  
 3015  
 3020  
 3025  
 3030  
 3035  
 3040  
 3045  
 3050  
 3055  
 3060  
 3065  
 3070  
 3075  
 3080  
 3085  
 3090  
 3095  
 3100  
 3105  
 3110  
 3115  
 3120  
 3125  
 3130  
 3135  
 3140  
 3145  
 3150  
 3155  
 3160  
 3165  
 3170  
 3175  
 3180  
 3185  
 3190  
 3195  
 3200  
 3205  
 3210  
 3215  
 3220  
 3225  
 3230  
 3235  
 3240  
 3245  
 3250  
 3255  
 3260  
 3265  
 3270  
 3275  
 3280  
 3285  
 3290  
 3295  
 3300  
 3305  
 3310  
 3315  
 3320  
 3325  
 3330  
 3335  
 3340  
 3345  
 3350  
 3355  
 3360  
 3365  
 3370  
 3375  
 3380  
 3385  
 3390  
 3395  
 3400  
 3405  
 3410  
 3415  
 3420  
 3425  
 3430  
 3435  
 3440  
 3445  
 3450  
 3455  
 3460  
 3465  
 3470  
 3475  
 3480  
 3485  
 3490  
 3495  
 3500  
 3505  
 3510  
 3515  
 3520  
 3525  
 3530  
 3535  
 3540  
 3545  
 3550  
 3555  
 3560  
 3565  
 3570  
 3575  
 3580  
 3585  
 3590  
 3595  
 3600  
 3605  
 3610  
 3615  
 3620  
 3625  
 3630  
 3635  
 3640  
 3645  
 3650  
 3655  
 3660  
 3665  
 3670  
 3675  
 3680  
 3685  
 3690  
 3695  
 3700  
 3705  
 3710  
 3715  
 3720  
 3725  
 3730  
 3735  
 3740  
 3745  
 3750  
 3755  
 3760  
 3765  
 3770  
 3775  
 3780  
 3785  
 3790  
 3795  
 3800  
 3805  
 3810  
 3815  
 3820  
 3825  
 3830  
 3835  
 3840  
 3845  
 3850  
 3855  
 3860  
 3865  
 3870  
 3875  
 3880  
 3885  
 3890  
 3895  
 3900  
 3905  
 3910  
 3915  
 3920  
 3925  
 3930  
 3935  
 3940  
 3945  
 3950  
 3955  
 3960  
 3965  
 3970  
 3975  
 3980  
 3985  
 3990  
 3995  
 4000  
 4005  
 4010  
 4015  
 4020  
 4025  
 4030  
 4035  
 4040  
 4045  
 4050  
 4055  
 4060  
 4065  
 4070  
 4075  
 4080  
 4085  
 4090  
 4095  
 4100  
 4105  
 4110  
 4115  
 4120  
 4125  
 4130  
 4135  
 4140  
 4145  
 4150  
 4155  
 4160  
 4165  
 4170  
 4175  
 4180  
 4185  
 4190  
 4195  
 4200  
 4205  
 4210  
 4215  
 4220  
 4225  
 4230  
 4235  
 4240  
 4245  
 4250  
 4255  
 4260  
 4265  
 4270  
 4275  
 4280  
 4285  
 4290  
 4295  
 4300  
 4305  
 4310  
 4315  
 4320  
 4325  
 4330  
 4335  
 4340  
 4345  
 4350  
 4355  
 4360  
 4365  
 4370  
 4375  
 4380  
 4385  
 4390  
 4395  
 4400  
 4405  
 4410  
 4415  
 4420  
 4425  
 4430  
 4435  
 4440  
 4445  
 4450  
 4455  
 4460  
 4465  
 4470  
 4475  
 4480  
 4485  
 4490  
 4495  
 4500  
 4505  
 4510  
 4515  
 4520  
 4525  
 4530  
 4535  
 4540  
 4545  
 4550  
 4555  
 4560  
 4565  
 4570  
 4575  
 4580  
 4585  
 4590  
 4595  
 4600  
 4605  
 4610  
 4615  
 4620  
 4625  
 4630  
 4635  
 4640  
 4645  
 4650  
 4655  
 4660  
 4665  
 4670  
 4675  
 4680  
 4685  
 4690  
 4695  
 4700  
 4705  
 4710  
 4715  
 4720  
 4725  
 4730  
 4735  
 4740  
 4745  
 4750  
 4755  
 4760  
 4765  
 4770  
 4775  
 4780  
 4785  
 4790  
 4795  
 4800  
 4805  
 4810  
 4815  
 4820  
 4825  
 4830  
 4835  
 4840  
 4845  
 4850  
 4855  
 4860  
 4865  
 4870  
 4875  
 4880  
 4885  
 4890  
 4895  
 4900  
 4905  
 4910  
 4915  
 4920  
 4925  
 4930  
 4935  
 4940  
 4945  
 4950  
 4955  
 4960  
 4965  
 4970  
 4975  
 4980  
 4985  
 4990  
 4995  
 5000  
 5005  
 5010  
 5015  
 5020  
 5025  
 5030  
 5035  
 5040  
 5045  
 5050  
 5055  
 5060  
 5065  
 5070  
 5075  
 5080  
 5085  
 5090  
 5095  
 5100  
 5105  
 5110  
 5115  
 5120  
 5125  
 5130  
 5135  
 5140  
 5145  
 5150  
 5155  
 5160  
 5165  
 5170  
 5175  
 5180  
 5185  
 5190  
 5195  
 5200  
 5205  
 5210  
 5215  
 5220  
 5225  
 5230  
 5235  
 5240  
 5245  
 5250  
 5255  
 5260  
 5265  
 5270  
 5275  
 5280  
 5285  
 5290  
 5295  
 5300  
 5305  
 5310  
 5315  
 5320  
 5325  
 5330  
 5335  
 5340  
 5345  
 5350  
 5355  
 5360  
 5365  
 5370  
 5375  
 5380  
 5385  
 5390  
 5395  
 5400  
 5405  
 5410  
 5415  
 5420  
 5425  
 5430  
 5435  
 5440  
 5445  
 5450  
 5455  
 5460  
 5465  
 5470  
 5475  
 5480  
 5485  
 5490  
 5495  
 5500  
 5505  
 5510  
 5515  
 5520  
 5525  
 5530  
 5535  
 5540  
 5545  
 5550  
 5555  
 5560  
 5565  
 5570  
 5575  
 5580  
 5585  
 5590  
 5595  
 5600  
 5605  
 5610  
 5615  
 5620  
 5625  
 5630  
 5635  
 5640  
 5645  
 5650  
 5655  
 5660  
 5665  
 5670  
 5675  
 5680  
 5685  
 5690  
 5695  
 5700  
 5705  
 5710  
 5715  
 5720  
 5725  
 5730  
 5735  
 5740  
 5745  
 5750  
 5755  
 5760  
 5765  
 5770  
 5775  
 5780  
 5785  
 5790  
 5795  
 5800  
 5805  
 5810  
 5815  
 5820  
 5825  
 5830  
 5835  
 5840  
 5845  
 5850  
 5855  
 5860  
 5865  
 5870  
 5875  
 5880  
 5885  
 5890  
 5895  
 5900  
 5905  
 5910  
 5915  
 5920  
 5925  
 5930  
 5935  
 5940  
 5945  
 5950  
 5955  
 5960  
 5965  
 5970  
 5975  
 5980  
 5985  
 5990  
 5995  
 6000  
 6005  
 6010  
 6015  
 6020  
 6025  
 6030  
 6035  
 6040  
 6045  
 6050  
 6055  
 6060  
 6065  
 6070  
 6075  
 6080  
 6085  
 6090  
 6095  
 6100  
 6105  
 6110  
 6115  
 6120  
 6125  
 6130  
 6135  
 6140  
 6145  
 6150  
 6155  
 6160  
 6165  
 6170  
 6175  
 6180  
 6185  
 6190  
 6195  
 6200  
 6205  
 6210  
 6215  
 6220  
 6225  
 6230  
 6235  
 6240  
 6245  
 6250  
 6255  
 6260  
 6265  
 6270  
 6275  
 6280  
 6285  
 6290  
 6295  
 6300  
 6305  
 6310  
 6315  
 6320  
 6325  
 6330  
 6335  
 6340  
 6345  
 6350  
 6355  
 6360  
 6365  
 6370  
 6375  
 6380  
 6385  
 6390  
 6395  
 6400  
 6405  
 6410  
 6415  
 6420  
 6425  
 6430  
 6435  
 6440  
 6445  
 6450  
 6455  
 6460  
 6465  
 6470  
 6475  
 6480  
 6485  
 6490  
 6495  
 6500  
 6505  
 6510  
 6515  
 6520  
 6525  
 6530  
 6535  
 6540  
 6545  
 6550  
 6555  
 6560  
 6565  
 6570  
 6575  
 6580  
 6585  
 6590  
 6595  
 6600  
 6605  
 6610  
 6615  
 6620  
 6625  
 6630  
 6635  
 6640  
 6645  
 6650  
 6655  
 6660  
 6665  
 6670  
 6675  
 6680  
 6685  
 6690  
 6695  
 6700  
 6705  
 6710  
 6715  
 6720  
 6725  
 6730  
 6735  
 6740  
 6745  
 6750  
 6755  
 6760  
 6765  
 6770  
 6775  
 6780  
 6785  
 6790  
 6795  
 6800  
 6805  
 6810  
 6815  
 6820  
 6825  
 6830  
 6835  
 6840  
 6845  
 6850  
 6855  
 6860  
 6865  
 6870  
 6875

shows all the materials that were assessed during the excipients compatibility study.

**Table 16: Excipient compatibility study list**

Material	Excipient:API Ratio	Material/grade	Main Function
Isomalt	100:1	GalenIQ 801	Filler
Pregelatinised starch	100:1	Starch 1500	Multifunctional
Lactose-starch	100:1	StarLac	Filler
Maltodextrin	100:1	Lycatab DSH	Multifunctional
Lactose anhydrous	100:1	Supertab 21AN	Filler
Hydroxypropyl cellulose	8:1	Klucel EXF	Dry binder
Hydroxypropyl methylcellulose	8:1	Methocel E5 Premium	Wet binder
PVP/VA 64	8:1	Kollidon VA64	Wet binder
Crospovidone	10:1	Kollidon CL	Disintegrant
Sodium starch glycolate	10:1	Explotab	Disintegrant
Sodium carbonate	8:1	Merck Darmstadt	pH modifier
Sodium citrate dihydrate	15:1	Merck Darmstadt	pH modifier
Magnesium oxide	8:1	Merck Darmstadt	pH modifier
Magnesium stearate	3:1	Mallinckrodt	Lubricant

5 All excipients were mixed with the API at ratios that are recommended to be used in a typical formulation, with or without addition of water, and placed in 55°C/75% RH for up to 4 weeks. In addition, 2 potential formulations with filler, binder, disintegrant, API and a lubricant were compressed into tablets and placed under  
10 the same conditions.

All batches were manufactured using the excipients evaluated in the past or in the current compatibility study, as listed in Tables 17 and 18, and varied in the percentage of each excipient and process parameters.

15 Table 17: Potential excipients and their percentage in the formulation

Chemical name	Grade	Function	Percentage
Isomalt	GalenIQ 721	Filler/diluent	0, 50, 100
Co processed lactose/starch	StarLac	Filler/diluent	0, 50, 100
Croscarmellose sodium	AC-DI-SOL	Disintegrant	5
Magnesium stearate	LIGAMED MF-2-V	Lubricant	1

Table 18: Potential excipients and their percentage in the formulation

Chemical name	Grade	Function	Percentage
Isomalt	GalenIQ 801	Filler/diluent	0, 50, 100
Mannitol	Pearlitol 200SD	Filler/diluent	0, 50, 100
Croscarmellose sodium	AC-DI-SOL	Disintegrant	5
Maltodextrin	Lycatab DSH	Wet binder	10
Sodium carbonate anhydrous	Merck EMPROVE Ph.Eur, BP, NF	Alkalizing agent	0, 2.5, 5
Magnesium oxide - heavy	Merck EMPROVE Ph.Eur, BP, NF	Alkalizing agent	0, 2.5, 5
Magnesium stearate	LIGAMED MF-2-V	Lubricant	1

5

A total of 21 batches were manufactured at this stage, which are divided into 4 processes for evaluation as of the following:

- (1) High shear dry mix - 6 batches.
- (2) Geometrical bin blending - 5 batches.
- (3) High shear wet granulation - 4 batches.
- (4) Top spray granulation - 6 batches.

10

Results obtained from dry and wet batches which did not contain an alkalizing agent, at 55°C/75% RH, showed a major decrease in assay and in impurities (Table 19 - Polar IDD) compared to Batch 16A (Table 14 and Table 15, formulated with mannitol as filler and without alkalizing agent) at the same conditions.

15

Table 19: Stability of various formulations at turbo conditions

Batch No.	Formulation	Appearance After 2 Weeks		Water Content (info only) (%)		Assay (95-105%) (%)		Total Impurities (NMT 2.0%) (%)	Dissolution (NLT 85% after 30 mins) (%)	
		55/75	40/75	T=0	T=2 weeks	T=0	T=2 weeks	T=2 weeks	30 mins	∞
11	Dry blend, 50/50 Isomalt/Starlac	White	White	3.8	4.2	101	89	3.1	86	86
12	Dry blend, Isomalt	White	White	2.6	2.8	95	77	6.7	75	75
13	Dry blend, Starlac	Slight brown discoloration on some tablets	White	5.2	5.2	97	93	1.6	92	92
14	Top spray granulation, 50/50 Isomalt/mannitol, no alkalizing agent	White	White	2.3	2.5	95	83	5.6	79	80
15	Dry Blend, Isomalt/mannitol	White	White	5.5	5.5	95	Pending	5.5	88	89

References

1. PCT International Application Publication No. WO 2005/074899, published August 18, 2005 (ACTIVE BIOTECH AB).
2. PCT International Application Publication No. WO 2007/047863,  
5 published April 26, 2007 (TEVA PHARMACEUTICAL INDUSTRIES, LTD.).
3. PCT International Application Publication No. WO/2007/146248, published December 21, 2007 (TEVA PHARMACEUTICAL INDUSTRIES, LTD.).
4. Polman et al., (2005) "Treatment with laquinimod reduces  
10 development of active MRI lesions in relapsing MS", Neurology.  
64:987-991.
5. Sandberg-Wollheim et al., (2005) "48-week open safety study with high-dose oral laquinimod in patients", Mult Scler.  
11:S154.
- 15 6. U.S. Patent Application Publication No. 2005/0192315, published September 1, 2005 (Jansson et al.).
7. U.S. Patent No. 6,077,851, issued June 20, 2000 to Anders Björk et al.
8. U.S. Patent No. 6,875,869, issued April 5, 2005 to Karl  
20 Jansson.
9. U.S. Patent No. 7,589,208, issued September 15, 2009 to Jansson et al.
10. U.S. Patent No. 7,884,208, issued February 8, 2011 to Anton Frenkel et al.
- 25 11. U.S. Patent No. 7,989,473, issued August 2, 2011 to Shulamit Patashnik et al.
12. U.S. Patent No. 8,178,127, issued May 15, 2012 to Muhammad Safadi et al.

**What is claimed is:**

1. A stable pharmaceutical composition comprising:
  - a) a therapeutically effective amount of laquinimod,
  - b) an amount of a filler, and
  - c) an amount of a lubricant,wherein the stable pharmaceutical composition is free of an alkalizing agent or an oxidation reducing agent.
2. The stable pharmaceutical composition of claim 1 in a solid form composition.
3. The stable pharmaceutical composition of claim 1 or 2, which is free of an alkalizing agent and which is free of an oxidation reducing agent.
4. The stable pharmaceutical composition of any one of claims 1-3, wherein the moisture content of the stable pharmaceutical composition is no more than 4%.
5. The stable pharmaceutical composition of claim 4, containing less than 1.5% wt H<sub>2</sub>O.
6. The stable pharmaceutical composition of claim 5, containing less than 0.5% wt H<sub>2</sub>O.
7. The stable pharmaceutical composition of any one of claims 1-6, wherein the total amount of non-polar impurities in the composition is less than 0.5 wt% relative to the amount of laquinimod.
8. The stable pharmaceutical composition of any one of claims 1-7, wherein the filler is present in the composition as solid particles.
9. The stable pharmaceutical composition of claim 8, wherein the filler is lactose, lactose monohydrate, starch, isomalt, mannitol, sodium starch glycolate, sorbitol, lactose spray

dried, lactose anhydrous, or a combination thereof.

10. The stable pharmaceutical composition of claim 9, wherein the filler is mannitol or lactose monohydrate.
11. The stable pharmaceutical composition of any one of claims 1-10, wherein the lubricant is present in the composition as solid particles.
12. The stable pharmaceutical composition of claim 11, wherein the lubricant is magnesium stearate or sodium stearyl fumarate.
13. The stable pharmaceutical composition of any one of claims 1-12, wherein the stable pharmaceutical composition is free of disintegrant.
14. The stable pharmaceutical composition of claim 13, wherein the stable pharmaceutical composition is free of croscarmellose sodium.
15. The stable pharmaceutical composition of any one of claims 1-14, wherein laquinimod is a pharmaceutically acceptable salt of laquinimod, which pharmaceutically acceptable salt is lithium salt, sodium salt or calcium salt.
16. The stable pharmaceutical composition of claim 15, wherein the pharmaceutically acceptable salt of laquinimod is laquinimod sodium.
17. The stable pharmaceutical composition of any one of claims 1-16, wherein laquinimod is present in the composition as solid particles.
18. The stable pharmaceutical composition of any one of claims 1-17, wherein the therapeutically effective amount of laquinimod is 0.25mg - 1.5mg.
19. The stable pharmaceutical composition of claim 18, wherein the therapeutically effective amount of laquinimod is 0.5mg.
20. The stable pharmaceutical composition of claim 18, wherein the

- therapeutically effective amount of laquinimod is 0.6mg.
21. The stable pharmaceutical composition of claim 18, wherein the therapeutically effective amount of laquinimod is 1.0mg.
  22. The stable pharmaceutical composition of claim 18, wherein the therapeutically effective amount of laquinimod is 1.2mg.
  23. The stable pharmaceutical composition of any one of claims 1-22, wherein the lubricant is between 0.5-2.0% of the total weight of the stable pharmaceutical composition.
  24. The stable pharmaceutical composition of any one of 1-23, wherein the filler is between 89.0-99.5% of the total weight of the stable pharmaceutical composition.
  25. The stable pharmaceutical composition of any one of claims 1-24, consisting essentially of laquinimod sodium, mannitol and magnesium stearate.
  26. The stable pharmaceutical composition of claim 25, comprising, by total weight of the pharmaceutical composition, 0.21-0.35% of the pharmaceutically acceptable salt of laquinimod, 89.0-99.5% mannitol, and 0.5-2.0% magnesium stearate.
  27. The stable pharmaceutical composition of claim 25, comprising, by total weight of the pharmaceutical composition, 0.15-0.35% of the pharmaceutically acceptable salt of laquinimod, 97.65-99.5% mannitol, and 0.5-2.0% magnesium stearate.
  28. The stable pharmaceutical composition of claim 26 or 27, comprising about 0.21% laquinimod sodium, about 98.80% mannitol and about 0.99% magnesium stearate.
  29. The stable pharmaceutical composition of claim 28, comprising 0.21% laquinimod sodium, 98.80% mannitol and 0.99% magnesium stearate.
  30. The stable pharmaceutical composition of claim 28, comprising about 0.64mg laquinimod sodium, about 300mg mannitol and about 3.0 mg magnesium stearate.

31. The stable pharmaceutical composition of claim 29 or 30, comprising 0.64mg laquinimod sodium, 300mg mannitol and 3.0 mg magnesium stearate.
32. The stable pharmaceutical composition of claim 27, comprising about 0.19% laquinimod sodium, about 98.94% mannitol and about 0.87% magnesium stearate.
33. The stable pharmaceutical composition of claim 32, comprising 0.19% laquinimod sodium, 98.94% mannitol and 0.87% magnesium stearate.
34. The stable pharmaceutical composition of any one of claims 17-33, wherein 10% or more of the total amount by volume of the laquinimod solid particles have a size of greater than 40 microns.
35. The stable pharmaceutical composition of any one of claims 17-34, wherein 50% or more of the total amount by volume of the laquinimod solid particles have a size of greater than 15 microns.
36. The stable pharmaceutical composition of any one of claims 1-35, in the form of a tablet.
37. The stable pharmaceutical composition of any one of claims 1-35, in the form of a capsule.
38. A process for making a stable pharmaceutical composition comprising a therapeutically effective amount of laquinimod, an amount of a filler and an amount of a lubricant, wherein the pharmaceutical composition is free of an alkalizing agent or an oxidation reducing agent, said process comprising:
  - a) obtaining the laquinimod, the lubricant and the filler;
  - b) mixing the laquinimod, the lubricant and the filler from step a) to achieve a dry mix free of an alkalizing agent or an oxidation reducing agent; and
  - c) compressing the dry mix of step b) to form a tablet.

39. The process of claim 38, comprising passing the lubricant through a mesh prior to step b).
40. The process of any one of claims 38 or 39, comprising passing the filler through a mesh prior to step b).
41. A process for making a stable pharmaceutical composition comprising a therapeutically effective amount of laquinimod, an amount of a filler and an amount of a lubricant, wherein the pharmaceutical composition is free of an alkalizing agent or an oxidation reducing agent, said process comprising:
- a) obtaining the laquinimod, the lubricant and the filler;
  - b) adding the filler to a mixer;
  - c) dissolving laquinimod in water to form a laquinimod solution;
  - d) adding the laquinimod solution of step c) to the mixer of step b);
  - e) mixing the laquinimod solution and the mannitol to form a granulate;
  - f) drying the granulate from step e) to form a dried granulate;
  - g) screening the dried granulate of step f);
  - h) milling the granulate resulting from step g) to form a milled granulate;
  - i) adding the lubricant to the milled granulate of step h) to form a mixture;
  - j) blending the mixture of step i) into a mixer to achieve a dry mix free of an alkalizing agent or an oxidation reducing agent; and
  - k) filling the dry mix of step j) into a capsule or compressing the dry mix of step j) to form a tablet.

42. The process of claim 41, comprising passing the lubricant through a mesh prior to step i).
43. The process of claim 41 or 42, comprising passing the filler through a mesh prior to step i).
44. A stable pharmaceutical composition comprising a therapeutically effective amount of laquinimod, an amount of a filler and an amount of a lubricant wherein the pharmaceutical composition is free of an alkalizing agent or an oxidation reducing agent, prepared by the process of any one of claims 38-43.
45. A sealed package comprising the stable pharmaceutical composition of any one of claims 1-37.
46. The sealed package of claim 45, further comprising a desiccant.
47. The sealed package of claim 46, wherein the desiccant is silica gel.
48. The sealed package of claim 46 or 47, which after storage at 40°C and at a relative humidity of 75% for 2 months contains less than 0.5 wt% of a degradant of laquinimod.
49. A sealed package containing a stable pharmaceutical composition comprising a therapeutically effective amount of laquinimod, an amount of a filler and an amount of a lubricant, wherein the pharmaceutical composition is free of an alkalizing agent or an oxidation reducing agent, and wherein the sealed package has a moisture permeability of not more than 9.2 mg/day per liter.
50. A method for treating a subject afflicted with a form of multiple sclerosis comprising administering to the subject the stable pharmaceutical composition of any one of claims 1-37 or 44 so as to thereby treat the subject.
51. A method for alleviating a symptom of multiple sclerosis in a subject afflicted with a form of multiple sclerosis comprising administering to the subject the stable pharmaceutical composition of any one of claims 1-37 or 44 so as to thereby

alleviate the symptom of multiple sclerosis in the subject.

52. Use of the stable pharmaceutical composition of any one of claims 1-37 or 44 for treating a subject afflicted with a form of multiple sclerosis.
53. Use of the stable pharmaceutical composition of any one of claims 1-37 or 44 for alleviating a symptom of multiple sclerosis in a subject afflicted with a form of multiple sclerosis.

**INTERNATIONAL SEARCH REPORT**

International application No.

PCT/US13/49894

<p><b>A. CLASSIFICATION OF SUBJECT MATTER</b>                  IPC(8) - A61K 31/47 (2013.01)                  USPC - 424/465; 514/311                  According to International Patent Classification (IPC) or to both national classification and IPC</p>		
<p><b>B. FIELDS SEARCHED</b></p>		
<p>Minimum documentation searched (classification system followed by classification symbols)                  IPC(8): A61K 31/47 (2013.01)                  USPC: 424/465; 514/311</p>		
<p>Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched                  IPC(8) - A61K 31/47 (2013.01)                  USPC - 424/465; 514/311</p>		
<p>Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)                  MicroPatent (US-G, US-A, EP-A, EP-B, WO, JP-bib, DE-C,B, DE-A, DE-T, DE-U, GB-A, FR-A); ProQuest Dialog; IP.com; Google Scholar; filler*, lubric*, laquinimod*, N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, free*, lack*, without*, alkaliz*, agent*, proton*, neutraliz*, sodium*, carbonate*, magnesium* oxide*, meglumine*, oxygen*, absorb*, scaveng*</p>		
<p><b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b></p>		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2009/0162432 A1 (SAFADI, M et al.) 25 June 2009; paragraphs [0003], [0062]-[0069], [0078], [0089]-[0090]	1-2, 38-39, 40/38-39, 41-42, 43/41-42
--		---
Y		3/1-2, 49
Y	US 2012/0009226 A1 (DIXIT, G et al.) 12 January 2012; paragraphs [0060]-[0069], [0085]	3/1-2
Y	US 2011/0251235 A1 (PATASHNIK, S et al.) 13 October 2011; paragraphs [0075], [0095]	49
<p><input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/></p>		
<p>* Special categories of cited documents:</p>		
"A"	document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E"	earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O"	document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P"	document published prior to the international filing date but later than the priority date claimed	
<p>Date of the actual completion of the international search                  12 November 2013 (12.11.2013)</p>		<p>Date of mailing of the international search report  <b>21 NOV 2013</b></p>
<p>Name and mailing address of the ISA/US                  Mail Stop PCT, Attn: ISA/US, Commissioner for Patents                  P.O. Box 1450, Alexandria, Virginia 22313-1450                  Facsimile No. 571-273-3201</p>		<p>Authorized officer:                  Shane Thomas                  PCT Helpdesk: 571-272-4300                  PCT OSP: 571-272-7774</p>

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US13/49894

**Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2.  Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
3.  Claims Nos.: 4-37, 44-48, and 50-53  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  
4.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

**Remark on Protest**

- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- No protest accompanied the payment of additional search fees.

CORRECTED VERSION

(19) World Intellectual Property  
Organization  
International Bureau



(10) International Publication Number  
**WO 2014/011750 A8**

(43) International Publication Date  
16 January 2014 (16.01.2014)

- (51) International Patent Classification:  
A61K 31/47 (2006.01)
- (21) International Application Number:  
PCT/US2013/049894
- (22) International Filing Date:  
10 July 2013 (10.07.2013)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
61/670,268 11 July 2012 (11.07.2012) US
- (71) Applicant (for all designated States except BB, US):  
**TEVA PHARMACEUTICAL INDUSTRIES LTD.**  
[IL/IL]; 5 Basel Street, P.O. Box 3190, 49131 Petach Tik-  
va (IL).
- (71) Applicant (for BB only): **TEVA PHARMACEUTICALS  
USA, INC.** [US/US]; 1090 Horsham Road, North Wales,  
PA 19454 (US).
- (72) Inventors; and
- (71) Applicants (for US only): **SARFATI, Gadi** [IL/IL]; Kib-  
butz Beit Guvrin (IL). **LOVINGER, Ioana** [IL/IL]; Rh.  
Tel Hai 98/3, 44245 Kfar Saba (IL). **LICHT, Danit**  
[IL/IL]; Rh. Keren Haysod 1, Givat Shmuel (IL). **SAFADI,  
Muhammad** [IL/IL]; c/o P.O. Box 50670, St. 5007 Apt.  
5A, 16164 Nazareth (IL).
- (74) Agent: **WHITE, John, P.**; Cooper & Dunham LLP, 30  
Rockefeller Plaza, New York, NY 10112 (US).
- (81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,  
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,  
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,  
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR,  
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,  
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,  
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC,  
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,  
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,  
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,  
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,  
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,  
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
KM, ML, MR, NE, SN, TD, TG).
- Published:  
— with international search report (Art. 21(3))
- (48) Date of publication of this corrected version:  
4 December 2014
- (15) Information about Correction:  
see Notice of 4 December 2014

(54) Title: LAQUINIMOD FORMULATIONS WITHOUT ALKALIZING AGENT

(57) Abstract: The subject invention provides a stable pharmaceutical composition comprising a therapeutically effective amount of laquinimod, an amount of a filler, and an amount of a lubricant, wherein the stable pharmaceutical composition is free of an alkalinizing agent or an oxidation reducing agent. The subject invention also provides processes for making the stable pharmaceutical composition and sealed packages comprising the stable pharmaceutical composition. The subject invention additionally provides method for treating a subject afflicted with a form of multiple sclerosis or for alleviating a symptom of multiple sclerosis in a subject afflicted with a form of multiple sclerosis comprising administering to the subject a stable pharmaceutical composition as described herein. The subject invention further provides for use of a stable pharmaceutical composition as described herein for treating a subject afflicted with a form of multiple sclerosis or for alleviating a symptom of multiple sclerosis in a subject afflicted with a form of multiple sclerosis.



WO 2014/011750 A8

## 摘要

本發明提供一種穩定的醫藥組合物，其包含治療有效量的拉喹莫德、一定量填充劑和一定量潤滑劑，其中所述穩定的醫藥組合物不含鹼化劑或氧化還原劑。本發明還提供一種用於製造所述穩定的醫藥組合物的方法和包含所述穩定的醫藥組合物的密封封裝。本發明另外提供用於治療罹患某一形式的多發性硬化的個體或用於減緩罹患某一形式的多發性硬化的個體的多發性硬化症狀的方法，所述方法包含向所述個體投與如本文所描述的穩定的醫藥組合物。本發明進一步提供如本文所描述的穩定的醫藥組合物的用途，其用於治療罹患某一形式的多發性硬化的個體或用於減緩罹患某一形式的多發性硬化的個體的多發性硬化症狀。